Am. J. Respir. Crit. Care Med., Volume 159, Number 3, March 1999, 733-740

Human Immunodeficiency Virus and the Outcome of Treatment for New and Recurrent Pulmonary Tuberculosis in African Patients

JILL MURRAY, PAMELA SONNENBERG, STUART C. SHEARER, and PETER GODFREY-FAUSSETT

National Centre for Occupational Health, Department of Health, Johannesburg; Gold Fields of South Africa, Johannesburg; Department of Community Health, University of the Witwatersrand, Parktown; Epidemiology Research Unit, Braamfontein, South Africa; ZAMBART Project, Department of Medicine, University Teaching Hospital, Lusaka, Zambia; and Department of Infectious and Tropical Diseases, School of Hygiene and Tropical Medicine, London, United Kingdom

The purpose of this study was to evaluate the impact of human immunodeficiency virus (HIV) infection on treatment for tuberculosis (TB). The study population comprised 28,522 black Southern African gold miners. Patients with sputum culture-positive new or recurrent pulmonary TB diagnosed in 1995 were prospectively enrolled in the cohort. Directly observed therapy (DOT) was practiced and outcomes were assessed at 6 mo after treatment was begun. There were 376 cases of TB (incidence 1,318 per 100,000), of which 190 (50%) were HIV positive and 82 (22%) had recurrent TB. There was no association between HIV status and history of previous TB or drug resistance. Neither the treatment interruption rate (2%) nor the rate at which patients transferred out of the treatment program (1.6%) were associated with HIV status. Excluding deaths, cure rates were similar for HIV-positive and HIV-negative patients (89% versus 88%), but significantly lower in those with recurrent than in those with new TB (77% versus 92%). Mortality was 0.5% in HIV-negative patients versus 13.7% in HIV-positive patients, and in the latter group was associated with CD4⁺ lymphocyte depletion. Autopsy examination showed that in HIV-positive patients, early mortality was due to TB whereas late deaths were most commonly due to cryptococcal pneumonia. The study showed that a well-run TB control program can result in acceptable cure rates even in a population with a very high incidence of TB and HIV infection. Particular vigilance is needed for concurrent infections, which may contribute significantly to mortality during treatment of TB in HIV-positive patients.

This article has been cited by other articles:

				W. Lew, M. Pai, O. Oxlade, D. Martin, and D. Menzies Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis Ann Intern Med, July 15, 2008; 149(2): 123 - 134. [Abstract] [Full Text] [PDF]

				E. Ribera, C. Azuaje, R. M. Lopez, P. Domingo, A. Curran, M. Feijoo, L. Pou, P. Sanchez, M. A. Sambeat, J. Colomer, et al. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis J. Antimicrob. Chemother., April 1, 2007; 59(4): 690 - 697. [Abstract] [Full Text] [PDF]

				K. Schwartzman, O. Oxlade, R. G. Barr, F. Grimard, I. Acosta, J. Baez, E. Ferreira, R. E. Melgen, W. Morose, A. C. Salgado, et al. Domestic Returns from Investment in the Control of Tuberculosis in Other Countries N. Engl. J. Med., September 8, 2005; 353(10): 1008 - 1020. [Abstract] [Full Text] [PDF]

				E. L. Corbett, C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C. Raviglione, and C. Dye The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic Arch Intern Med, May 12, 2003; 163(9): 1009 - 1021. [Abstract] [Full Text] [PDF]

				American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF]

				R Colebunders and M L Lambert Management of co-infection with HIV and TB BMJ, April 6, 2002; 324(7341): 802 - 803. [Full Text] [PDF]

				Tuberculosis and HIV AIDS Clinical Care, February 1, 2002; 2002(201): 6 - 6. [Full Text]

				W. J. BURMAN and B. E. JONES Treatment of HIV-related Tuberculosis in the Era of Effective Antiretroviral Therapy Am. J. Respir. Crit. Care Med., July 1, 2001; 164(1): 7 - 12. [Abstract] [Full Text] [PDF]

				A. Bandera, A. Gori, L. Catozzi, A. D. Esposti, G. Marchetti, C. Molteni, G. Ferrario, L. Codecasa, V. Penati, A. Matteelli, et al. Molecular Epidemiology Study of Exogenous Reinfection in an Area with a Low Incidence of Tuberculosis J. Clin. Microbiol., June 1, 2001; 39(6): 2213 - 2218. [Abstract] [Full Text] [PDF]